Friedreich's Ataxia Publication and NeurologyToday Article

I am excited to announce the publication of our paper, establishing the initial clinical validity of using wearable sensors for at-home monitoring of upper and lower limb dysfunction and assessing disease severity in Friedreich's ataxia (FRDA).

Published today in Communications Medicine, our study demonstrates significant correlations, with moderate to high effect sizes, between multiple sensor-derived metrics and clinical and biological outcomes (i.e., GAA and FXN) in FRDA. Additionally, we present machine learning-based models that accurately predict disease severity using demographic, biological, and sensor-derived metrics.

I am also pleased to share an article published earlier this month in NeurologyToday, which highlights the development and application of our BioDigit MG solution—a multimodal digital health technology designed to monitor symptoms in myasthenia gravis (MG). In the article, Dr. Amanda Guidon, MD, MPH, Chief of the Division of Neuromuscular Medicine and Director of the MG Program at Massachusetts General Hospital, provides insights into BioDigit MG's development and discusses its initial clinical validation study. This study received the 2024 AANEM President’s Research Initiative Award earlier this month.